Larger and longer studies in broader populations are needed to fully understand the safety and efficacy in people with alcohol use disorder, but these initial findings are promising. About this study: In addition to Hendershot and Klein, other authors of the study are Michael Bremmer, Michael Paladino, Georgios Kostantinis, Thomas Gilmore, Neil Sullivan, Amanda Tow and Robyn Jordan, all of University of North Carolina at Chapel Hill
Diagnostic Bias Doctors may be more likely to consider NAION in patients taking GLP-1s, leading to more frequent diagnoses
Find activities you enjoy, like walking, swimming, biking, or dancing
"Insurers should be prepared to help plan sponsors on that matter," he added
Methods We used a combination of glucagon secretion measurements in mouse and human islets (including islets from donors with type 2 diabetes), total internal reflection fluorescence microscopy imaging of secretory granule dynamics, recordings of cytoplasmic Ca 2+ and measurements of protein kinase A activity, immunocytochemistry, in vivo physiology and GTP-binding protein dissociation studies to explore how GLP-1 exerts its inhibitory effect on glucagon secretion and the role of the metabolite GLP-1(936)
